The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1 dose-escalation study of EC1456, a folic acid-tubulysin small-molecule drug conjugate, in adult patients (pts) with advanced solid tumors.
Wael A. Harb
Research Funding - Horizon Oncology Research
Ramesh K. Ramanathan
Research Funding - Endocyte
Daniela E. Matei
No relevant relationships to disclose
Binh Nguyen
Employment or Leadership Position - Endocyte
Stock Ownership - Endocyte
Edward A. Sausville
Research Funding - Endocyte